Skip to content

Welcome to Discover Pharma! Today is : October 22, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Alzheimer’s Disease

  • Digital & Data,Research & Development,Therapeutic Areas

    Study supports home-based EEG platform for Alzheimer’s clinical trials

    A peer-reviewed study has demonstrated that Cumulus Neuroscience’s NeuLogiq platform [...]

    July 3, 2026
  • Advanced Therapies,Biotech & Pharma Business,Central Nervous System,Drug Discovery & Development

    TRIMTECH raises $14M to advance protein degradation therapies for neurodegenerative diseases

    TRIMTECH Therapeutics has secured an additional $14 million in seed [...]

    June 23, 2026
  • Digital & Data,Medical devices,Therapeutic Areas

    Sysmex launches automated Alzheimer’s blood testing platform in Europe

    Sysmex Europe has launched its HISCL automated immunoassay platform for [...]

    June 17, 2026
  • Biotech & Pharma Business,Central Nervous System,Drug Discovery & Development

    Deep Science Ventures and Medicines Discovery Catapult target blood-brain barrier challenge

    Deep Science Ventures and Medicines Discovery Catapult have launched a [...]

    June 6, 2026
  • Clinical & Regulatory,Digital & Data,Therapeutic Areas

    Scotland launches accredited Alzheimer’s biomarker testing service

    Scottish Brain Sciences (SBS) has launched an accredited laboratory service [...]

    June 6, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    AC Immune amends Lilly collaboration on Tau small molecules for Alzheimer’s disease

    AC Immune has amended its collaboration agreement with Eli Lilly [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    AC Immune doses first participant in Phase 1 trial of NLRP3 inhibitor ACI-19764

    AC Immune has initiated a Phase 1 trial of its [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Exciva raises €51 million Series B to fund phase 2 Alzheimer’s agitation trial

    Exciva GmbH has raised €51 million ($59m) in a Series [...]

    May 5, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development,Medical devices,Pharmaceuticals and therapeutics

    From awareness to action: Linus Health drives next era of early brain health detection

    Linus Health is accelerating its efforts in early brain health [...]

    May 5, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Therapeutic Areas

    Linus Health to present AI-driven brain health research at CTAD 2025

    Linus Health, an AI-driven brain health company focused on early [...]

    May 5, 2026
Previous123Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • SurVaxM improves survival in Phase 2b glioblastoma trial
    Categories: Central Nervous System, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Lab-grown human neuromuscular junctions advance MND drug discovery
    Categories: Research & Development, Therapeutic Areas
  • Olink assay correlates with ELISA for measuring endothelin-1
    Categories: Clinical & Regulatory, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top